Alpha Tau Medical (DRTS) Clinical Progress Tests Whether The Stock Already Looks Fully Valued

Alpha Tau Medical earnings put recent clinical progress in context

Alpha Tau Medical (NasdaqCM:DRTS) has paired a series of high profile clinical and partnership milestones with fresh half year results that show a wider net loss and higher loss per share.

The company reported a net loss of US$68.75 million for the half year to June 30, 2026, compared with a loss of US$18.81 million a year earlier. Basic and diluted loss per share from continuing operations were both US$0.76, compared with US$0.25 per share in the prior period.

See our latest analysis for Alpha Tau Medical.

Against this backdrop of clinical and partnership updates, Alpha Tau Medical’s share price has moved sharply, with a 195.45% year to date share price return and a 339.08% total shareholder return over the past year. This indicates strong momentum building behind the stock at a current price of US$14.27.

If Alpha Tau Medical’s recent surge has caught your attention, it may be a good time to see what else is moving in the sector through our screener of 43 healthcare AI stocks

After that kind of surge, and with Alpha Tau Medical still reporting sizeable losses, the trade off between clinical promise and valuation risk looks very different. Does the current price still leave enough on the table for new buyers?

Preferred Price-to-Book Multiple of 19x: Is it justified?

With Alpha Tau Medical closing at $14.27 and a price target of $14.40, the stock is trading very close to where covering analysts have set expectations. However, the current valuation stands out more clearly when you look at the price-to-book multiple rather than the headline price.

The preferred multiple here is the P/B ratio, which compares the company’s market value to its book value. Alpha Tau Medical is trading on a P/B of 19x, which is one of the few concrete valuation markers available given that the company is unprofitable and reports no revenue.

A P/B of 19x suggests investors are placing a high value on Alpha Tau Medical’s clinical pipeline and technology relative to its current balance sheet. With losses increasing over the past five years and the company forecast to remain unprofitable in three years, that multiple reflects a strong belief in future progress rather than current financial performance.

Compared with the US Medical Equipment industry average of 2.5x and a peer average of 4.7x, Alpha Tau Medical’s 19x P/B is significantly higher. The market is pricing the stock at several times the level implied by both its sector and peers, which sets a high bar for future execution to support this valuation.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Preferred multiple of price-to-book of 19x (OVERVALUED)

However, Alpha Tau Medical still carries clear risks, including ongoing losses of US$56.875 million and reliance on clinical trial outcomes that could alter investor confidence.

Find out about the key risks to this Alpha Tau Medical narrative.

Next Steps

With both risks and rewards in play for Alpha Tau Medical, it makes sense to move quickly and look through the details yourself. To see how the key concerns and potential upsides balance out, review the 1 key reward and 4 important warning signs

Looking for more Alpha Tau Medical style investment ideas?

If Alpha Tau Medical has you thinking about what else is out there, use the Simply Wall Street Screener to uncover other stocks that might fit your approach.

• Scan for companies that combine quality with attractive pricing through the 51 high quality undervalued stocks.
• Prioritise stability by checking out the 83 resilient stocks with low risk scores and see which stocks score well on resilience.
• Hunt for lesser known opportunities with strong fundamentals using the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com